SG10202106190RA - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents

Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Info

Publication number
SG10202106190RA
SG10202106190RA SG10202106190RA SG10202106190RA SG10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA
Authority
SG
Singapore
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
cognitive function
Prior art date
Application number
SG10202106190RA
Other languages
English (en)
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of SG10202106190RA publication Critical patent/SG10202106190RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG10202106190RA 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function SG10202106190RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19

Publications (1)

Publication Number Publication Date
SG10202106190RA true SG10202106190RA (en) 2021-07-29

Family

ID=58633040

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202106190RA SG10202106190RA (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
SG11201809031XA SG11201809031XA (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201809031XA SG11201809031XA (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Country Status (26)

Country Link
US (4) US10905670B2 (https=)
EP (2) EP4501406A3 (https=)
JP (3) JP7387264B2 (https=)
KR (4) KR102791288B1 (https=)
CN (2) CN109069463B (https=)
AU (2) AU2017252507B2 (https=)
BR (1) BR112018071547A2 (https=)
CA (1) CA3021155A1 (https=)
DK (1) DK3445351T3 (https=)
ES (1) ES2994242T3 (https=)
FI (1) FI3445351T3 (https=)
HR (1) HRP20241552T1 (https=)
HU (1) HUE069219T2 (https=)
IL (3) IL310508A (https=)
LT (1) LT3445351T (https=)
MD (1) MD3445351T2 (https=)
MX (2) MX388461B (https=)
PL (1) PL3445351T3 (https=)
PT (1) PT3445351T (https=)
RS (1) RS66142B1 (https=)
RU (1) RU2745912C2 (https=)
SG (2) SG10202106190RA (https=)
SI (1) SI3445351T1 (https=)
SM (1) SMT202400459T1 (https=)
WO (1) WO2017182802A1 (https=)
ZA (1) ZA201806849B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
WO2020178721A1 (en) * 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
US20250099355A1 (en) 2023-07-18 2025-03-27 Sytheon Ltd Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
CA2687107A1 (en) * 2007-05-08 2008-11-13 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
US20120196257A1 (en) * 2009-08-27 2012-08-02 Joe Verghese Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
US12458614B2 (en) * 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Also Published As

Publication number Publication date
EP4501406A2 (en) 2025-02-05
IL293266B2 (en) 2024-07-01
KR20240018683A (ko) 2024-02-13
IL293266A (en) 2022-07-01
DK3445351T3 (da) 2024-11-04
AU2017252507B2 (en) 2022-07-21
BR112018071547A2 (pt) 2019-03-06
KR20220093386A (ko) 2022-07-05
HRP20241552T1 (hr) 2025-01-17
SI3445351T1 (sl) 2025-04-30
CA3021155A1 (en) 2017-10-26
RU2745912C2 (ru) 2021-04-02
RU2018140131A3 (https=) 2020-05-14
LT3445351T (lt) 2024-11-25
IL262379B (en) 2022-07-01
SMT202400459T1 (it) 2025-01-14
ES2994242T3 (en) 2025-02-05
US20210106548A1 (en) 2021-04-15
CN109069463B (zh) 2024-07-23
KR102791288B1 (ko) 2025-04-03
US20190083438A1 (en) 2019-03-21
US10905670B2 (en) 2021-02-02
MX2018012739A (es) 2019-06-17
US20230346732A1 (en) 2023-11-02
EP3445351B1 (en) 2024-10-16
RU2021107001A (ru) 2021-04-12
PT3445351T (pt) 2024-11-14
US20250332133A1 (en) 2025-10-30
CN118593463A (zh) 2024-09-06
AU2022256077A1 (en) 2022-11-17
KR102413754B1 (ko) 2022-06-27
JP2022024058A (ja) 2022-02-08
IL310508A (en) 2024-03-01
US11998518B2 (en) 2024-06-04
IL293266B1 (en) 2024-03-01
ZA201806849B (en) 2019-07-31
NZ747307A (en) 2025-10-31
JP7387264B2 (ja) 2023-11-28
RS66142B1 (sr) 2024-12-31
JP2024123087A (ja) 2024-09-10
KR20220038814A (ko) 2022-03-29
EP3445351A1 (en) 2019-02-27
RU2018140131A (ru) 2020-05-14
MX2021014844A (es) 2022-01-18
US12329733B2 (en) 2025-06-17
WO2017182802A1 (en) 2017-10-26
KR20180134398A (ko) 2018-12-18
JP2019513814A (ja) 2019-05-30
JP7506046B2 (ja) 2024-06-25
EP4501406A3 (en) 2025-03-26
KR102632670B1 (ko) 2024-02-01
HUE069219T2 (hu) 2025-02-28
SG11201809031XA (en) 2018-11-29
CN109069463A (zh) 2018-12-21
IL262379A (en) 2018-11-29
MD3445351T2 (ro) 2024-12-31
MX388461B (es) 2025-03-20
PL3445351T3 (pl) 2025-01-07
AU2017252507A1 (en) 2018-11-08
FI3445351T3 (fi) 2024-11-18

Similar Documents

Publication Publication Date Title
IL262107B (en) Overlapping bangs
ZA202103713B (en) Mobility procedure
SG10202106190RA (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
HUE048993T2 (hu) Ágy csökkent mobilitással rendelkezõ személyek számára
HUE049523T2 (hu) Peszticidként hatásos szemikarbazon- és tioszemikarbazon-származékok
IL272808B (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
ZA201904241B (en) Novel compound and pharmacologically acceptable salt thereof
IL272385A (en) Drug compound and methods of preparation
ZA201906258B (en) Therapeutic compounds and methods
GB201617064D0 (en) Compounds and their therapeutic use
IL265269B (en) New compounds and their medicinal uses
NO2024058I1 (no) delgocitinib or a pharmaceutically acceptable salt thereof
IL267937A (en) Amide compounds and their use
ZA201805743B (en) Hla-b57 open conformers
GB201616370D0 (en) Wireless handover system
ZA201806247B (en) Beta-caseins and cognitive function
HUE057818T2 (hu) Azaindolilpiridon és diazaindolilpiridon vegyületek
GB201700404D0 (en) Compounds and composistions
GB2539264B (en) Mobility aid
GB201720115D0 (en) Mobility aid
GB201617063D0 (en) Condoms
IL265617B (en) 1-phenylpropanone compounds and their use
PT3630997T (pt) Monitorização terapêutica de fármacos
GB201720943D0 (en) New processes and compounds
GB201702051D0 (en) New Pharmaceutical use